These findings not only underscore the importance of splicing in AMKL cell survival, but also support the oncogenic role of RBM39 in AMKL, which is consistent with research across various tumor types including AML [25], liver cancer [26], and high-risk neuroblastoma [40]. This evidence concerns the gene RBM39 and acute myeloid leukemia.